Advantagene Enters Clinical Trial Collaboration With Bristol-Myers Squibb

(RTTNews) - Advantagene, Inc. announced the company entered into a clinical trial collaboration with Bristol-Myers Squibb (BMY) to evaluate the safety, tolerability, and preliminary efficacy of Advantagene's investigational Gene Mediated Cytotoxic Immunotherapy in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor, Opdivo (nivolumab), in newly diagnosed malignant glioma patients receiving standard of care surgery and radiation with or without temozolomide.

Advantagene is a Massachusetts based biotechnology company developing its Gene Mediated Cytotoxic Immunotherapy platform technology for the treatment of solid tumors.

"GMCI by itself showed very promising survival benefits in our recent Phase 2 brain cancer study. This is the next step, the first human study evaluating the potential benefits of combining the immune-stimulatory properties of GMCI with an immune checkpoint inhibitor," said Estuardo Aguilar-Cordova, CEO of Advantagene.